+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Active, Not Recruiting

Phase 3
Age: 18Years +
All Genders
ID05211895

A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab Plus DomvanalimabAB154 in Participants With Locally Advanced Stage III, Unresectable Non-small Cell Lung Cancer Whose Disease Has Not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy

Led by AstraZeneca · Updated on 2026-08-28

791

Participants Needed

226

Research Sites

56 weeks

Total Duration

AI-Summary

What This Trial Is About

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.

CONDITIONS

Brief Title

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here